论文部分内容阅读
为了观察食欲刺激剂甲地孕酮（ｍｅｇｅｓｔｒｏｌａｃｅｔａｔｅ，ＭＡ）对慢性阻塞性肺病（ＣＯＰＤ）缓解期患者营养状况、呼吸肌力及免疫功能的影响，将３１例患者随机分为两组，治疗组１６例，口服ＭＡ１６０ｍｇ／ｄ；对照组１５例，口服多酶片３片。治疗前后测定饮食营养指标、肺功能、呼吸肌力和有关免疫学参数。２周后发现每日摄入热能和蛋白质有显著增加；人体测量值如体重、理想体重百分比、三头肌皮褶厚度、血清蛋白测定值、最大口腔吸气压、最大口腔呼气压、握力、６分钟行走距离、淋巴细胞直接计数、淋巴细胞转化率和肺活量占预计值百分比等的变化与治疗前比较，差异有显著性（Ｐ＜０．０１）。对照组１５例患者各项指标均无明显变化。用药后仅１例患者有轻微恶心呕吐。说明ＭＡ可改善ＣＯＰＤ缓解期患者营养状况、呼吸肌力及免疫功能。
In order to observe the effect of megestrolacetate (MA) on nutritional status, respiratory muscle strength and immune function in patients with chronic obstructive pulmonary disease (COPD) remission, 31 patients were randomly divided into two groups. Treatment group 16 Cases, oral MA160mg / d; control group of 15 cases, oral multi-enzyme tablets 3 tablets. Dietary and nutritional indices, lung function, respiratory muscle strength and related immunological parameters were measured before and after treatment. After 2 weeks, daily intake of calories and protein were significantly increased; body measurements such as body weight, percentage of ideal body weight, triceps skinfold thickness, serum protein measurements, maximal oral suction pressure, maximal oral breath pressure, grip strength , 6-minute walking distance, direct count of lymphocytes, lymphocyte transformation rate and the percentage of predicted vital capacity of lung were compared with before treatment, the difference was significant (P <0.01). The control group of 15 patients with no significant changes in the indicators. Only one patient after treatment had mild nausea and vomiting. MA can improve the nutritional status of patients with COPD remission, respiratory muscle strength and immune function.